miR-193b regulates tumorigenesis in liposarcoma cells via PDGFR, TGFβ, and Wnt signaling

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Liposarcoma is the most common soft tissue sarcoma.
• Current molecularly targeted therapies for liposarcoma show limited efficacy due to complex tumor alterations.
• MicroRNA-193b (miR-193b) has been identified as a tumor suppressor in liposarcoma.

Purpose of the Study:

• To confirm the under-expression of miR-193b in liposarcoma.
• To identify and validate direct targets of miR-193b in liposarcoma.
• To investigate the therapeutic potential of targeting miR-193b pathways in liposarcoma.

Main Methods:

• Confirmation of miR-193b under-expression in patient samples and cell lines.
• STRING analysis to predict protein-protein interactions of miR-193b targets.
• Validation of PDGFRβ, SMAD4, and YAP1 as direct miR-193b targets.
• Assessment of the effects of inhibiting PDGFRβ, SMAD4, and YAP1 on liposarcoma cells.

Main Results:

• miR-193b is significantly under-expressed in liposarcoma.
• PDGFRβ, SMAD4, and YAP1 were validated as direct targets of miR-193b.
• Inhibition of PDGFRβ reduced cell viability and increased adipogenesis.
• SMAD4 knockdown promoted adipogenic differentiation.
• miR-193b targeting of YAP1 indirectly inhibited Wnt/β-catenin signaling.
• PDGFR and Wnt/β-catenin inhibitors demonstrated potent anti-liposarcoma effects.

Conclusions:

• miR-193b acts as a tumor suppressor in liposarcoma by targeting multiple key signaling pathways.
• Targeting PDGFRβ and Wnt/β-catenin signaling pathways holds promise for liposarcoma treatment.